Achievement of NKF/K-DOQI Recommended Target Values for Bone and Mineral Metabolism in Incident Hemodialysis Patients: Results of the FARO-2 Cohort

被引:16
作者
Cozzolino, Mario [1 ]
Messa, Piergiorgio [2 ]
Brancaccio, Diego [3 ]
Cannella, Giuseppe [4 ]
Bolasco, Piergiorgio [5 ]
Di Luca, Marina [6 ]
Costanzo, Anna Maria [7 ]
Paparatti, Umberto di Luzio [7 ]
Festa, Vincenzo [7 ]
Gualberti, Giuliana [7 ]
Mazzaferro, Sandro [8 ]
机构
[1] Univ Milan, Dept Hlth Sci, San Paolo Hosp, Div Renal, IT-20142 Milan, Italy
[2] Fdn Ca Granda IRCCS Policlin, Milan, Italy
[3] Dialysis Unit Simone Martini, Milan, Italy
[4] San Martino Hosp, Dept Nephrol, Genoa, Italy
[5] ASL Cagliari, Terr Nephrol & Dialysis Unit, Cagliari, Italy
[6] Osped Riuniti Marche Nord, UOC Nephrol Dialysis, Pesaro, Italy
[7] AbbVie SrL Italy, Latina, Italy
[8] Univ Roma La Sapienza, Dipartimento Sci Cardiovasc Resp Nefrol & Geriatr, I-00185 Rome, Italy
关键词
Mineral Bone Disorders; NKF/K-DOQI; Incident haemodialysis; Survival; CHRONIC KIDNEY-DISEASE; VITAMIN-D; SECONDARY HYPERPARATHYROIDISM; PARATHYROID-HORMONE; DIALYSIS PATIENTS; MORTALITY RISK; CARDIOVASCULAR-DISEASE; PHOSPHATE PRODUCT; ORAL PARICALCITOL; PRACTICE PATTERNS;
D O I
10.1159/000365386
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Mineral Bone Disorders (MBD) is prevalent in hemodialysis (HD) patients and associated with increased cardiovascular mortality. The FARO-2 study evaluated the achievement of the NKF/K-DOQI guidelines on recommended target values for serum calcium (Ca), phosphorous (P) and intact parathyroid hormone (PTH) levels on survival in incident HD patients. Methods: Data were collected by questionnaire from 568 incident HD patients followed prospectively over a 3-year period from 26 Italian dialysis units. The cumulative probability of time-to-death for CKD-MBD treatment characteristics was determined by the Kaplan-Meier curves. Results: Serum PTH levels (median values at 6 months vs. 36 months; 225 vs. 254 pg/ml), Ca (8.8 vs. 8.9 g/dl) and P (5.1 vs. 4.8 mg/dl) were not significantly different at 6 months versus follow-up. The majority of incident HD patients (60-70%) who were followed up for 36 months did not achieve the NKF/K-DOQI recommended target values. Survival rates were higher in patients on target for three parameters versus patients off target (survival at 24 months: at target 95.7% (95% CI: 84.0-98.9) versus not on target 71.1% (95% CI: 66.3-75.4, p < 0.01)). The 30.1% of patients on target for three MBD parameters at least once during the follow-up period had better survival rates compared to those not reaching these targets (survival at 24 months: at least once 88.0% (95% CI: 81.9-92.1); 67.7% (95% CI: 61.9-72.8, p < 0.01)). Conclusion: Our findings indicate that incident HD patients who achieved target levels (for three MBD parameters) for at least one visit have a lower risk of mortality. (C) 2014 S. Karger AG, Basel
引用
收藏
页码:37 / 45
页数:9
相关论文
共 51 条
  • [1] Arenas MD, 2007, J NEPHROL, V20, P453
  • [2] Mineral metabolism, mortality, and morbidity in maintenance hemodialysis
    Block, GA
    Klassen, PS
    Lazarus, JM
    Ofsthun, N
    Lowrie, EG
    Chertow, GM
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (08): : 2208 - 2218
  • [3] Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study
    Block, GA
    Hulbert-Shearon, TE
    Levin, NW
    Port, FK
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (04) : 607 - 617
  • [4] Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism
    Block, Geoffrey A.
    Zeig, Steven
    Sugihara, Jared
    Chertow, Glenn M.
    Chi, Eric M.
    Turner, Stewart A.
    Bushinsky, David A.
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2008, 23 (07) : 2311 - 2318
  • [5] Predictors of early mortality among incident US hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS)
    Bradbury, Brian D.
    Fissell, Rachel B.
    Albert, Justin M.
    Anthony, Mary S.
    Critchlow, Cathy W.
    Pisoni, Ronald L.
    Port, Friedrich K.
    Gillespie, Brenda W.
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 2 (01): : 89 - 99
  • [6] Secondary Hyperparathyroidism in Chronic Dialysis Patients: Results of the Italian FARO Survey on Treatment and Mortality
    Brancaccio, Diego
    Cozzolino, Mario
    Cannella, Giuseppe
    Messa, Piergiorgio
    Bonomini, Mario
    Cancarini, Giovanni
    Caruso, Maria Rosa
    Cascone, Carmelo
    Costanzo, Anna Maria
    Paparatti, Umberto di Luzio
    Mazzaferro, Sandro
    [J]. BLOOD PURIFICATION, 2011, 32 (02) : 124 - 132
  • [7] Drug Insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease
    Brown, Alex J.
    Slatopolsky, Eduardo
    [J]. NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2007, 3 (02): : 134 - 144
  • [8] Capuano A, 2009, J NEPHROL, V22, P59
  • [9] Cozzolino M, 2012, NEPHROL DIAL TRANSPL, V27, pii1
  • [10] VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH ≤ 150 pg/mL: results of the Italian FARO Survey
    Cozzolino, Mario
    Brancaccio, Diego
    Cannella, Giuseppe
    Messa, Piergiorgio
    Gesualdo, Loreto
    Marangella, Martino
    LoDeserto, Cosimo
    Pozzato, Marco
    Rombola, Giuseppe
    Costanzo, Anna Maria
    Paparatti, Umberto di Luzio
    Mazzaferro, Sandro
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 (09) : 3588 - 3594